Papular granuloma annulare associated with tirzepatide: A case report Authors: Tara Howard, Amanda Clichy-Silva, Francisco Kerdel Published: 2026 Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for the management of type 2 diabetes mellitus and obesity due to their efficacy in improving glycemic control, reducing body weight, and lowering cardiovascular risk. Tirzepatide, a dual glucose-dependent insulinotropic peptide/GLP-1 receptor agonist, was approved by the U.S. Food and Drug Administration in 2022. While gastrointestinal effects such as nausea and diarrhea are well known, dermatologic adverse events remain incompletely characterized.1 We present a rare case of papular granuloma annulare (GA) associated with tirzepatide therapy. Case presentation A 44-year-old woman with no significant medical history presented with a 2-week history of a pruritic eruption involving the upper extremities and trunk. She denied systemic symptoms, recent infections, or new exposures. Her only medication was tirzepatide 7.5 mg weekly for weight loss, which she had been taking consistently for four months; the eruption developed 3 days after completing her fourth month of therapy. On examination, multiple annular papules were noted on the arms (Figs 1 and 2), and chest. The patient had no mucosal involvement or constitutional symptoms (fever, malaise) or preceding infectious trigger. Given the annular morphology and acute onset, early erythema multiforme was initially considered. However, the absence of classic targetoid lesions, mucosal involvement, and a preceding infectious trigger made EM less likely, prompting consideration of alternative diagnoses. Initial visit - bilateral upper extremities. Multiple discrete to coalescing annular papules distributed symmetrically on the bilateral arms, consistent with papular granuloma annulare. Initial visit – left forearm. Closer view demonstrating skin-colored to erythematous papules with associated excoriations on the left forearm, highlighting the pruritic nature of the eruption. A 4 mm punch biopsy was performed, and topical triamcinolone 0.1% cream twice daily was initiated. Two weeks later, the patient returned to our clinic, and it appeared the eruption partially improved but new painful lesions developed on the hands and feet (Fig 3). She received a 40 mg intramuscular injection of triamcinolone acetonide, and tirzepatide was discontinued. The eruption completely resolved within 15 days without recurrence. Follow-up information was obtained via telephone four months after treatment, at which time the patient reported sustained resolution. Follow-up visit 2 weeks later – hands. Development of new annular papules involving the dorsal hands and interdigital web spaces, indicating progression of the eruption. Histopathology revealed palisading granulomas with central mucin deposition, collagen degeneration, and lymphohistiocytic infiltrate, consistent with papular GA (Fig 4). Periodic acid–Schiff and acid-fast bacillus stains were negative Histopathology – left distal dorsal forearm. Biopsy specimen demonstrating features consistent with granuloma annulare, including palisading histiocytes surrounding areas of necrobiotic collagen with associated mucin deposition within the dermis. Discussion GA is a benign inflammatory dermatosis of uncertain etiology. A Th1-mediated delayed hypersensitivity response has been proposed, triggered by various stimuli including trauma, infections, vaccinations, and medications. Reported drug-induced cases include those associated with allopurinol, gold, and tumor necrosis factor-α inhibitors.2 In addition, emerging reports suggest a possible association between GLP-1 receptor agonists and granulomatous or GA-like eruptions, including prior cases reported with semaglutide, raising the possibility of a class effect.3 Although GA has been associated with systemic diseases such as diabetes mellitus, thyroid disorders, and autoimmune conditions, causality remains uncertain.2, 3, 4 In this case, the strong temporal correlation between drug exposure and eruption onset, absence of alternative triggers, and complete resolution following drug discontinuation support a likely causal association. Application of the Naranjo adverse drug reaction probability scale yielded a score consistent with a probable drug-induced reaction, further strengthening this relationship. The pathophysiology of drug-induced GA remains incompletely understood but is thought to involve immune dysregulation leading to granulomatous inflammation and collagen degeneration.2,4 GLP-1 receptor agonists may influence immune pathways through modulation of cytokine signaling and macrophage activation, potentially promoting a delayed-type hypersensitivity response in susceptible individuals.5 Similar mechanisms have been proposed in other medication-induced GA cases, particularly those involving biologic agents, suggesting a shared pathway of immune-mediated granuloma formation. Diagnosis of GA relies on clinicopathologic correlation. While localized GA often resolves spontaneously or with topical corticosteroids, more widespread or symptomatic cases may require systemic therapy.2,4 Recognition of potential medication-induced GA, particularly in the setting of newer agents such as GLP-1 receptor agonist, is important to facilitate timely identification, avoid unnecessary interventions, and prevent recurrence with continued exposure. Conclusion The expanding use of dual glucose-dependent insulinotropic peptide/GLP-1 receptor agonists such as tirzepatide for weight loss underscores the importance of recognizing potential cutaneous adverse effects. Although systemic hypersensitivity reactions have been reported as rare in clinical trials and case reports, this case raises the possibility of an association between tirzepatide and granuloma annulare.1,6 Clinicians should consider medication-induced etiologies in patients presenting with new-onset granulomatous eruptions while receiving GLP-1–based therapies. Continued reporting of such events to pharmacovigilance systems is essential to improve understanding of potential class effects and to ensure ongoing patient safety. Conflicts of interest None disclosed. Footnotes Funding sources: None. Patient consent: The authors obtained written consent from the patient(s) for their photographs and medical information to be published in print and online, with the understanding that this information may be publicly available. Patient consent forms were not provided to the journal but are retained by the authors. IRB approval status: This article was exempt from IRB approval. References